Baxter’s REVACLEAR Dialyzer May Offer New Benefits
A new study of 37,500 HD patient records found that use of a REVACLEAR high flux dialyzer was linked to the need for 100 to 600 fewer units of ESA per treatment than matched patients who used an Optiflux® 160 or 180 dialyzer. Researchers also noted a trend toward lower IV iron doses with the Revaclear—while keeping the same HD dose and hemoglobin level.
Read the full article » | Posted 08-09-2016
Related Articles
- 30th European Nephrology Conference will be held August 27-28 in Berlin Posted 02-17-2026
- An Australian PD patient developed the free Dialysis Health Tracker app Posted 02-17-2026
- Education Critical to Boosting Home Dialysis, Panel Says I Posted 01-16-2026
- The Annual Dialysis Conference Will be in Kansas City, MO February 26 to March 1 Posted 01-16-2026

